Skip to content

Effects of Pakistani and American almonds on good cholesterol

Comparison of high-density lipoprotein (HDL) raising efficacy of Pakistani and American almonds in Coronary artery disease patients with sub-optimal HDL

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12614000036617
Acronym
CHEPAA
Enrollment
119
Registered
2014-01-16
Start date
2013-02-11
Completion date
2013-06-28
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Coronary artery disease patients with normal lipids and below-normal HDL will be recruited in one of the three arms. They will be given either Pakistani or american almonds or no intervention if they are randomized in the control group. Blood will be drawn at baseline, six and twelve weeks for lipid profiling. HDL-raising efficacy of almonds and comparison of the two almond varieties will be analyzed

Interventions

Arm 1: No intervention Arm 2: Pakistani almonds (10 gm per day for 12 weeks) Arm 3: American almonds (10 gm per day for 12 weeks) The content of different almond varieties vary which might or might not lead to difference in biological activity. Total duration of intervention is 12 weeks. Regular phone calls (twice a week) were made to monitor compliance.

Sponsors

Aga Khan University
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
0 to No maximum
Healthy volunteers
No

Inclusion criteria

Coronary artery disease with LDL < = 100 mg/dl and HDL < = 40 mg/dl (male) or < = 50 mg/dl (female)

Exclusion criteria

All patients recently presented with Acute Myocardial infarction (within last 5 weeks). Patients with nut allergy Patients already taking regular nuts Regular Smokers

Outcome results

None listed

Source: ANZCTR · Data processed: Mar 15, 2026